Levosimendan: a review of its use in the management of acute decompensated heart failure (Q35592393)

9 August 2017

1 reference

title

Levosimendan: a review of its use in the management of acute decompensated heart failure (English)

1 reference

Acute decompensated heart failure

9 August 2017

0 references

1 reference

2

Antona J Wagstaff

1 reference

9 August 2017

Carmen A Innes

1

1 reference

PubMed ID

14636085

9 August 2017

language of work or name

1 reference

1 January 2003

1 reference

9 August 2017

1 reference

9 August 2017

63

1 reference

9 August 2017

23

1 reference

9 August 2017

2651-2671

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200363230-00009

9 August 2017

0 references

cites work

The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis

1 reference

12 December 2020

The contractility enhancing effect of the calcium sensitiser levosimendan is not attenuated by carvedilol in healthy subjects

1 reference

12 December 2020

Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study.

1 reference

12 December 2020

Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men.

1 reference

12 December 2020

Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties.

1 reference

12 December 2020

Guidelines for the diagnosis and treatment of chronic heart failure

1 reference

12 December 2020

Effect of long-term oral pretreatment with levosimendan on cardiac arrhythmias during coronary artery occlusion in conscious rats

1 reference

12 December 2020

Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I.

1 reference

12 December 2020

Myocardial efficiency during levosimendan infusion in congestive heart failure.

1 reference

12 December 2020

Recent advances in the treatment of heart failure

1 reference

12 December 2020

Beneficial effects of the Ca(2+) sensitizer levosimendan in human myocardium

1 reference

12 December 2020

Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction

1 reference

12 December 2020

Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties

1 reference

12 December 2020

Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators

1 reference

12 December 2020

Haemodynamic dose-efficacy of levosimendan in healthy volunteers.

1 reference

12 December 2020

Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligation and reperfusion in the in vivo pig model

1 reference

12 December 2020

Haemodynamic interactions between the novel calcium sensitiser levosimendan and isosorbide-5-mononitrate in healthy subjects

1 reference

12 December 2020

Levosimendan: a new era for inodilator therapy for heart failure?

1 reference

12 December 2020

Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic interrelationships of intravenous and oral levosimendan in patients with severe congestive heart failure

1 reference

12 December 2020

Levosimendan is a mitochondrial K(ATP) channel opener

1 reference

12 December 2020

Effect of a calcium-sensitizing agent, levosimendan, on the postcardioplegic inotropic response of the myocardium

1 reference

12 December 2020

Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: structure-response and binding analysis with analogs of levosimendan

1 reference

12 December 2020

Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart

1 reference

12 December 2020

Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.

1 reference

12 December 2020

Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).

1 reference

12 December 2020

Electrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function

1 reference

12 December 2020

Calcium-dependent vasorelaxant capacity of levosimendan in porcine and human epicardial coronary artery preparations

1 reference

12 December 2020

Myocardial efficiency during calcium sensitization with levosimendan: A noninvasive study with positron emission tomography and echocardiography in healthy volunteers*

1 reference

12 December 2020

Sustained hemodynamic effects of intravenous levosimendan

1 reference

12 December 2020

1 reference

12 December 2020

Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium.

1 reference

12 December 2020

Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart

1 reference

12 December 2020

The CYP3A4 inhibitor intraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan

1 reference

12 December 2020

Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein

1 reference

12 December 2020

Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.

1 reference

12 December 2020

Studies on psychomotoric effects and pharmacokinetic interactions of the new calcium sensitizing drug levosimendan and ethanol

1 reference

12 December 2020

Population pharmacokinetics of levosimendan in patients with congestive heart failure

1 reference

12 December 2020

Effect of the calcium sensitizer levosimendan on the performance of ischaemic myocardium in anaesthetised pigs

1 reference

12 December 2020

Safety of levosimendan and other calcium sensitizers

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers

1 reference

12 December 2020

Drug binding to cardiac troponin C

1 reference

12 December 2020

Mechanisms of action of calcium-sensitizing drugs

1 reference

12 December 2020

Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy

1 reference

12 December 2020

Comparison of the effects of levosimendan, pimobendan, and milrinone on canine left ventricular-arterial coupling and mechanical efficiency

1 reference

12 December 2020

ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Gu

1 reference

12 December 2020

Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs.

1 reference

12 December 2020

Levosimendan improves diastolic and systolic function in failing human myocardium.

1 reference

12 December 2020

Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs.

1 reference

12 December 2020

Mechanisms of the contractile effects of levosimendan in the mammalian heart

1 reference

12 December 2020

Effects of OR-1896, an active metabolite of levosimendan, on contractile force and aequorin light transients in intact rabbit ventricular myocardium

1 reference

12 December 2020

An analysis of responses to levosimendan in the pulmonary vascular bed of the cat.

1 reference

12 December 2020

Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure

1 reference

12 December 2020

Binding of levosimendan, a calcium sensitizer, to cardiac troponin C.

1 reference

12 December 2020

The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan

1 reference

12 December 2020

Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure

1 reference

12 December 2020

Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels

1 reference

12 December 2020

Pharmacotherapeutic approaches for decompensated heart failure: a role for the calcium sensitiser, levosimendan?

1 reference

12 December 2020

Levosimendan increases L-type Ca(2+) current via phosphodiesterase-3 inhibition in human cardiac myocytes

1 reference

12 December 2020

Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril

1 reference

12 December 2020

Interaction of levosimendan with cardiac troponin C in the presence of cardiac troponin I peptides

1 reference

12 December 2020

Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization

1 reference

12 December 2020

Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals

1 reference

12 December 2020

Classification of positive inotropic actions based on electrophysiologic characteristics: where should calcium sensitizers be placed?

1 reference

12 December 2020

Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan

1 reference

12 December 2020

Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure.

1 reference

12 December 2020

Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium

1 reference

12 December 2020

Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics

1 reference

12 December 2020

Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation.

1 reference

12 December 2020

Drug treatment of patients with decompensated heart failure

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitiser levosimendan and warfarin

1 reference

12 December 2020

1 reference

12 December 2020

Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.

1 reference

12 December 2020

Intracoronary levosimendan enhances contractile function of stunned myocardium

1 reference

12 December 2020

The effects of levosimendan on [Ca2+]i in guinea-pig isolated ventricular myocytes

1 reference

12 December 2020

10.2165/00003495-200363230-00009

Identifiers

DOI

1 reference

PubMed ID

14636085

Dimensions Publication ID

9 August 2017

0 references

1 reference

PubMed ID

14636085